TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Hepatocellular carcinoma (HCC) is a globally prevalent malignancy with limited therapeutic outcomes from current treatments.
• Adoptive cellular therapies (ACTs), particularly T-cell receptor (TCR)-T therapy, are emerging as a significant area of research for cancer treatment.

Purpose of the Study:

• To review the epidemiology of HCC and evaluate current first-line treatment efficacy.
• To introduce TCR-T therapy as a potential treatment for HCC.
• To categorize existing TCR-T research based on antigen targets for HCC treatment.

Main Methods:

• Comprehensive literature review of published studies on TCR-T therapy for HCC.
• Analysis of registered clinical trials investigating TCR-T therapy in HCC.
• Categorization of research by specific antigen targets utilized in TCR-T therapy.

Main Results:

• Identification and categorization of various antigen targets being explored for TCR-T therapy in HCC.
• Overview of the current landscape of published literature and clinical trials in this field.
• Discussion of limitations and challenges associated with current TCR-T research and applications in HCC.

Conclusions:

• TCR-T therapy demonstrates significant promise as a future treatment modality for HCC.
• Further research and development are necessary to overcome existing challenges and optimize TCR-T therapy for HCC.
• Antigen targeting is a critical aspect in the advancement of TCR-T therapy for hepatocellular carcinoma.